ARGENX SE
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 42.2
- Dividend yield
- –
About Argenx
Biological Products, (No Diagnostic Substances), SIC 2836
The provided filing excerpt contains raw XBRL taxonomy identifiers and accounting data tags without any narrative corporate descriptions. Consequently, the excerpt does not disclose the company's business activities, main products, commercial services, operating segments, or customer base. The taxonomy references include equity items, share-based payment plans, and asset categories, but omit descriptive operational context.
The excerpt also provides no operational metrics, facility counts, geographic presence, or corporate headquarters location. While accounting tags reference Belgian tax regulations in the context of share awards, no geographic reach or headquarters details are disclosed in the text. Furthermore, the text does not state the founding year or an official website address.
Summary of the business section of Argenx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ARGENX SE
- Headquarters
- Zwijnaarde, Belgium
- Address
- Industriepark Zwijnaarde 7, Building C B-9052
- Phone
- (329) 310-3400
- Employees
- 1,863, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- EY Accountants B.V., Eindhoven, the Netherlands
Stock & identifiers
- Ticker
- ARGX
- Exchange
- Nasdaq
- IPO date
- May 19, 2017
- Shares outstanding
- 62M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1697862
- CUSIP
- 04016X101
- ISIN
- US04016X1019
- LEI
- 7245009C5FZE6G9ODQ71
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Argenx's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“• Expansion to 1,863 full-time employees (as of December 31, 2025) to support further growth of our business,”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 6, 2026 | Tender offer | Third-party tender offer for the company's shares |
| May 19, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| May 16, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 21, 2017 | Name change | Name changed from argenx N.V to ARGENX SE |